Evidence map›Paper›PMID 32156020›Full record

ArticleMolecules (Basel, Switzerland)2020

Evaluation of Organo [

Sofia Otaru, Surachet Imlimthan, Mirkka Sarparanta, Kerttuli Helariutta, Kristiina Wähälä, Anu J Airaksinen

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.9field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Development ofPharmaceuticals (Basel, Switzerland) · 2022
    Article
  6. Site-Specific and Residualizing Linker forJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2021
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Sofia OtaruDepartment of Chemistry, Radiochemistry, University of Helsinki, 00100 Helsinki, Finland.
Surachet ImlimthanDepartment of Chemistry, Radiochemistry, University of Helsinki, 00100 Helsinki, Finland.ORCID 0000-0003-2520-2146
Mirkka SarparantaDepartment of Chemistry, Radiochemistry, University of Helsinki, 00100 Helsinki, Finland.ORCID 0000-0002-2956-4366
Kerttuli HelariuttaDepartment of Chemistry, Radiochemistry, University of Helsinki, 00100 Helsinki, Finland.ORCID 0000-0002-4143-912X
Kristiina WähäläDepartment of Chemistry, Radiochemistry, University of Helsinki, 00100 Helsinki, Finland.ORCID 0000-0003-4082-8622
Anu J AiraksinenDepartment of Chemistry, Radiochemistry, University of Helsinki, 00100 Helsinki, Finland.ORCID 0000-0002-5943-3105
University of Helsinki · FI

Funding

Academy of Finland 278056Academy of Finland 298481Academy of Finland 306239Helsingin Yliopisto a three year research grant
6 · The paper itself

Abstract

Fluorine-18 is the most widely used positron emission tomography (PET) radionuclide currently in clinical application, due to its optimal nuclear properties. The synthesis of

Indexed as

AnimalsBlood ProteinsCycloaddition ReactionCyclooctanesDrug StabilityFemaleFluorine RadioisotopesHumansMagnetic Resonance SpectroscopyMicePositron-Emission TomographyRadiopharmaceuticalsSerum Albumin, BovineSiliconTissue DistributionBlood ProteinsCyclooctanesFluorine-18Fluorine RadioisotopesRadiopharmaceuticalsSerum Albumin, BovineSiliconbioorthogonal chemistryfluorine-18inverse electron-demand Diels-Alder ligationisotopic exchangepositron emission tomography (PET), defluorinationsilicon-based fluoride acceptortetrazine

Identifiers

PMID32156020
PMCPMC7179430
OpenAlexW3009746678

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.